Rapid and Precise Diagnosis of Retroperitoneal Liposarcoma with Deep-Learned Label-Free Molecular Microscopy Article / By Wiley Knowledge Hub Rapid and Precise Diagnosis of Retroperitoneal Liposarcoma with Deep-Learned Label-Free Molecular Microscopy Read More »
Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas Article / By Wiley Knowledge Hub Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas Read More »
Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma Article / By Wiley Knowledge Hub Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma Read More »
Paraneoplastic syndrome due to dedifferentiated liposarcoma producing granulocyte colony-stimulating factor and interleukin-6 Article / By Wiley Knowledge Hub Paraneoplastic syndrome due to dedifferentiated liposarcoma producing granulocyte colony-stimulating factor and interleukin-6 Read More »
Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report Article / By Wiley Knowledge Hub Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report Read More »
Treatment of patients with dedifferentiated liposarcoma (DDLPS) with the MDM2–p53 antagonist brigimadlin and p53 function: A longitudinal analysis of circulating microRNAs (miRNAs) in a first-in-human phase Ia/Ib study Article / By Wiley Knowledge Hub Treatment of patients with dedifferentiated liposarcoma (DDLPS) with the MDM2–p53 antagonist brigimadlin and p53 function: A longitudinal analysis of circulating microRNAs (miRNAs) in a first-in-human phase Ia/Ib study Read More »
Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma (SS), myxoid liposarcoma (MLPS) and de-differentiated liposarcoma (DDLPS): A single-arm phase 2 trial Article / By Wiley Knowledge Hub Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma (SS), myxoid liposarcoma (MLPS) and de-differentiated liposarcoma (DDLPS): A single-arm phase 2 trial Read More »
A phase 2 trial of the CDK4 inhibitor dalpiciclib in well-differentiated or dedifferentiated liposarcoma Article / By Wiley Knowledge Hub A phase 2 trial of the CDK4 inhibitor dalpiciclib in well-differentiated or dedifferentiated liposarcoma Read More »
Proteomic analysis in patients with dedifferentiated liposarcoma (DDLPS) in a phase Ia/Ib study of the MDM2–p53 antagonist brigimadlin Article / By Wiley Knowledge Hub Proteomic analysis in patients with dedifferentiated liposarcoma (DDLPS) in a phase Ia/Ib study of the MDM2–p53 antagonist brigimadlin Read More »
Molecular characteristics of dedifferentiated liposarcoma with broad rhabdomyosarcomatous differentiation Article / By Wiley Knowledge Hub Molecular characteristics of dedifferentiated liposarcoma with broad rhabdomyosarcomatous differentiation Read More »
